Enterprise Value

361M

Cash

315.2M

Avg Qtr Burn

-33.07M

Short % of Float

20.43%

Insider Ownership

1.47%

Institutional Own.

91.78%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
FT825/ONO-8250 Details
Solid tumor/s, Cancer

Phase 1

Data readout

Phase 1

Data readout

FT819 (CAR-19, TCR-KO) Details
B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia

Phase 1

Data readout

Phase 1

Update

FT819 (CAR-19, TCR-KO) Details
Systemic lupus erythematosus

Phase 1

Initiation

FT516 (NK cells - engineered CD16 FcR) Details
Solid tumor/s, B-cell lymphoma, Diffuse large B cell lymphoma

Failed

Discontinued

FT596 (CAR19, hnCD16, IL-15RF) + rituximab Details
B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia

Failed

Discontinued

FT596 (CAR19, hnCD16, IL-15RF) + R-CHOP Details
B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia

Failed

Discontinued

FT500 (PD1/PD-L1) Details
Solid tumor/s, Cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

ProTmune (CD34+) Details
Acute graft-versus host disease

Failed

Discontinued